Intra-Cellular Therapies (ITCI) – Company Press Releases
-
Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
-
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
-
Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
-
Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
-
Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference
-
Intra-Cellular Therapies Reports Fourth Quarter And Full-Year 2023 Financial Results And Provides Corporate Update
-
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
-
Intra-Cellular Therapies to Present at the 6th Annual Evercore ISI HealthCONx Conference
-
Intra-Cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
-
Intra-Cellular Therapies to Host Third Quarter 2023 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Intra-Cellular Therapies Announces Presentations at Psych Congress 2023 Including Positive Results from Study 403 in Mixed Features
-
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
-
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
-
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
-
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
-
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
-
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
-
Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the SVB Securities Global Biopharma Conference
-
Intra-Cellular Therapies to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Intra-Cellular Therapies Highlights New CAPLYTA Bipolar Depression Data Presentations at the American College of Neuropsychopharmacology 61st Annual Meeting
-
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
-
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host Second Quarter 2022 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies Highlights Lumateperone Bipolar Depression Data Presentations at the 2022 International Society for Bipolar Disorders (ISBD) Experience
-
Intra-Cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host First Quarter 2022 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
-
Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors
-
Intra-Cellular Therapies to Present at the 21st Annual Needham Virtual Healthcare Conference
-
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
-
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
-
Intra-Cellular Therapies to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Intra-Cellular Therapies Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Intra-Cellular Therapies Prices Public Offering of Common Stock
-
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Back to ITCI Stock Lookup
